PASITHEA THERAPEUTICS CORP. (KTTA)
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
VENUs Ford Amphitheater Reports Exceptional Premium Seating Performance Across Back-to-Back Shows
HASI Prices $1 Billion of 5.950% Green Senior Unsecured Notes Due 2033
Mobileye To Establish Vertically Integrated Robotaxi Business
Nebius completes acquisition of Eigen AI
Best Buy Canada Selects Perion as a Full-Stack Partner to Power its Retail DOOH Media Network
SD Government announces Federal Aviation Administration STC approval for Gogo Galileo HDX installation on the Pilatus PC-12
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave